Real World and Epidemiology Study of Medically Attended Chlamydia Trachomatis Among Adults in Germany

Sanofi

Status: Active, not recruiting

Conditions: Chlamydia Trachomatis

Study type: Observational

Funder types: Industry

Identifiers

NCT07002047

U1111-1320-4648 (Other Identifier)

VAV00049

Details and patient eligibility

About

This study assesses the epidemiologic situation of chlamydia trachomatis, its complications and long term sequalae and related healthcare resource utilization and costs among adults in Germany.

The study is a retrospective cohort study based on German Statutory Health Insurance (SHI) claims data for adolescents and adults aged 14 to 44 years in the years 2008-2022 with documented (confirmed) diagnosis of CT.

Study Objectives are to:

1. Estimate frequency of potential short-term complications and long-term sequelae in patients with medically attended chlamydia infection
2. Analyze time from first documented prevalent CT infection to first potential complication/sequelae diagnosis
3. Estimate frequency of re-infection (chlamydia recurrence) and co-infections with other sexually transmitted infections (STIs) in patients with medically-attended chlamydia infection
4. Estimate absolute healthcare resource utilization (by level of care and specialty) and costs in patients with chlamydia infection, including for potential short-term complications and long-term sequelae
5. Estimate administrative prevalence of medically-attended chlamydia infection in the overall study population
6. Estimate administrative prevalence of diagnoses potentially associated with a chlamydia infection (i.e., short-term complications/long-term sequelae) in the overall study population
7. Estimate frequency of chlamydia testing in the overall study population

Enrollment: 81,239 patients

Sex: All

Ages: 14 to 44 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Either male or female is documented as gender in base data
• At cohort entry, a patient must be aged between 14 and 44 years

Exclusion criteria

• None

Trial design

81,239 participants in 1 patient group

Male and Female Adolescents and Adults with CT

Description:

Male and Female patients aged between 14 and 44 years of age with documented (confirmed) CT diagnosis